<DOC>
	<DOCNO>NCT00609674</DOCNO>
	<brief_summary>The purpose study compare effect ( effectiveness safety ) intranasal corticosteroid ( fluticasone furoate nasal spray [ FFNS ] ) , placebo nasal spray treatment perennial ( year-round ) allergic rhinitis .</brief_summary>
	<brief_title>A Clinical Study To Test A Nasal Spray ( Fluticasone Furoate Nasal Spray ) For The Treatment Of Perennial ( Year-round ) Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : Informed consent Subject provide appropriately sign date informed consent . An appropriately sign dated assent must obtain parent guardian subject child 18 year age . Outpatient Subject treatable outpatient basis . Age ≥ 12 year Visit 2 ≥ 18 year Visit 1 Russia Germany Male eligible female . Female subject enrol plan become pregnant time study participation . A urine pregnancy test perform female childbearing potential Visits 1 , 2 , 5 , Visit 6/Early Withdrawal determine subject pregnant . To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control , define follow : Abstinence Females childbearing potential sexually active must commit complete abstinence intercourse two week exposure study drug , throughout clinical trial , period trial account elimination drug ( minimum six day ) . Oral contraceptive ( either combine estrogen/progestin progestin ) , Injectable progestogen , Implants levonorgestrel , Percutaneous contraceptive patch , Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year , Male partner sterile ( vasectomy documentation azospermia ) prior female subject 's entry study sole sexual partner female subject , Double barrier methodcondom occlusive cap ( diaphragm cervical /vault cap ) plus spermicide , Estrogenic vaginal ring Diagnosis PAR include : A positive skin test ( prick method ) response appropriate perennial allergen ( house dust mite , animal dander , mold , cockroach ) within last 12 month prior Visit 1 Visit 1 . A positive skin test define wheal ≥3mm large diluent control prick test . Two year medical history past treatment PAR ( write verbal confirmation ) include perennial , i.e. , yearround , symptom . PAR symptom would include nasal congestion , rhinorrhea , nasal itch sneezing , eye itching/burning , eye tearing/watering , eye redness . In vitro test specific IgE ( RAST , PRIST ) allow diagnosis PAR . NOTE : Subjects meet criterion PAR also history allergy seasonal pollen present geographic area study participation NOT eligible randomization . Environment Subject must symptomatic appropriate perennial allergen ( animal dander , house dust mite , cockroach , mold ) willing maintain environment throughout study . Ability comply study procedure Subject understand willing , able likely comply study procedure restriction . Literate Subject must able read , comprehend , record information English native language . Randomization Criteria At Visit 2 , subject must meet following criterion : Average last 8 rTNSS assessment ( 4 AM assessment , 4 PM assessment ) four 24hours period prior randomization must ≥6 . This include AM assessment morning randomization visit . Average last 8 reflective nasal symptom assessment congestion ( 4 AM assessment , 4 PM assessment ) four 24hour period prior randomization must ≥2 . This include AM assessment morning randomization visit . Average last eight rTOSS assessment ( 4 AM assessment , 4 PM assessment ) four 24hour period prior randomization must ≥ 4 . This include AM assessment morning randomization visit . The subject demonstrate ability comply use daily ediary , define completion least 80 % assessment screening period . Subjects meet follow criterion must enrol study : Significant concomitant medical condition , define limited : historical current evidence clinically significant uncontrolled disease body system ( e.g. , tuberculosis , psychological disorder , eczema ) . Significant defined disease , opinion investigator , would put safety subject risk study participation would confound interpretation study result disease/condition exacerbate study . severe physical obstruction nose ( e.g. , deviated septum nasal polyp ) nasal septal perforation could affect deposition double blind intranasal study drug nasal ( e.g. , nasal septum ) ocular injury/surgery last 3 month asthma , exception mild intermittent asthma [ NAEPP , 2007 ; GINA , 2006 ] , mild asthma ( Canada ) [ Lemiére , 2004 ] . NOTE : Subjects allow use shortacting inhaled beta2 agonists ONLY need basis . rhinitis medicamentosa bacterial viral infection ( e.g. , common cold ) eye upper respiratory tract within two week Visit 1 screening period document evidence acute significant chronic sinusitis , determine individual investigator current history glaucoma and/or ocular herpes simplex current cataract physical impairment would affect subject 's ability participate safely fully study clinical evidence Candida infection nose history psychiatric disease , intellectual deficiency , poor motivation , substance abuse ( include drug alcohol ) condition limit validity inform consent would confound interpretation study result history adrenal insufficiency Use corticosteroid , define : Intranasal corticosteroid within 4 week prior Visit 1 ( e.g. , FLONASE™ , VERAMYST , Nasonex , Rhinocort ) . Inhaled , oral , intramuscular , intravenous , ocular , and/or dermatological corticosteroid ( exception hydrocortisone cream/ointment , 1 % less , equivalent ) within 8 week prior Visit 1 . Use allergy medication within timeframe indicated relative Visit 1 Intranasal ocular cromolyn within 14 day prior Visit 1 ( e.g. , Nasalcrom , Crolom ) Shortacting prescription nonprescription antihistamine , include ocular preparation antihistamine contain insomnia `` night time '' pain formulation , within 3 day prior Visit 1 ( e.g. , Benadryl , Chlortrimeton , Dimetane , Tavist ) Longacting antihistamine within 10 day prior Visit 1 , include loratadine , desloratadine , fexofenadine , cetirizine , levocetirizine , terfenadine ( e.g. , Allegra , Claritin , Clarinex , Zyrtec ) Longacting antihistamine , astemizole , within 12 week prior Visit 1 Intranasal antihistamine ( e.g. , Astelin ) within 2 week prior Visit 1 Oral intranasal decongestant within 3 day prior Visit 1 ( e.g. , Sudafed ) Longacting betaagonists within 3 day prior Visit 1 ( e.g. , SEREVENT™ , Foradil ) Intranasal , oral , inhaled anticholinergic within 3 day prior Visit 1 ( e.g. , Atrovent ) Histamine H2receptor antagonists include cimetidine , ranitidine , famotidine , nizatidine ( e.g. , ZANTAC™ , Tagamet , Pepcid , Axid ) within 1 day prior Visit 1 Oral antileukotrienes within 3 day Visit 1 ( e.g. , Singulair ) Subcutaneous omalizumab ( Xolair ) within 5 month Visit 1 Subjects permit use artificial tear , eyewashes/nasal irrigation solution , homeopathic preparation , lubricant , sympathomimetic vasoconstrictor preparation screen treatment period . No exclusion period prior screen ( Visit 1 ) require treatment . Use medication may affect allergic rhinitis symptom Chronic use concomitant medication , tricyclic antidepressant , would affect assessment effectiveness study drug Use intranasally administer medication ( e.g. , Miacalcin ) Use immunosuppressive medication eight week prior screen study Immunotherapy Immunotherapy patient may enrol study long immunotherapy initiate within 30 day Visit 1 dose remain fixed 30 day prior Visit 1 , dose remain fixed duration study . Use medication significantly alter pharmacokinetics fluticasone furoate , include ritonavir ketoconazole Allergy/Intolerance Known hypersensitivity corticosteroid , excipients product Use contact lens Use Nasal Continuous Positive Airway Pressure ( CPAP ) device ( mask pillow ) Clinical trial/experimental medication experience Participation clinical trial within 12 month prior Visit 1 Participation previous current FFNS ( GW685698X ) clinical study Positive pregnancy test female breastfeeding Has positive inconclusive pregnancy test Visit 1 Visit 2 Affiliation investigational site Subject participate investigator , subinvestigator , study coordinator , employee participate investigator , immediate family member aforementioned . Current tobacco use Subject currently use , use within past year , smoking product include cigarette , cigar , pipe chew tobacco . Chickenpox measles A subject eligible he/she currently chickenpox measles , expose chickenpox measles last three week nonimmune . If subject develop chickenpox measles study , he/she withdrawn study . If nonimmune subject expose chickenpox measles study , his/her continuation study discretion investigator , take consideration likelihood develop active disease . Findings clinically significant , abnormal electrocardiogram ( ECG ) Findings clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Perennial allergic rhinitis ; fluticasone furoate nasal spray</keyword>
</DOC>